

GLOBAL REACH

Medpace has the global reach and capability to conduct studies and assist with regulatory requirements throughout the world.

FOCUS: CENTRAL AND EASTERN EUROPE

MEDPACE

THE ADVANTAGE OF **FOCUS**



FOCUS: CENTRAL AND EASTERN EUROPE

Central and Eastern Europe Partnerships

Overview

Central and Eastern Europe (CEE) provides numerous incentives for clinical trial research. With large accessible populations, centralized healthcare systems, excellent investigational sites, and high-quality, low-cost data collection, CEE offers Medpace and its sponsors a competitive advantage in expedited timelines and cost efficiencies. Led by a staff of physicians and cardiologists from the region, Medpace has responded proactively to these incentives and the rising number of successful trials in the area by establishing operations in CEE countries.

Recruitment

With a population of over 300 million, and the majority living in highly concentrated urban areas, CEE countries have excelled in-patient recruitment opportunities. In addition, the region has a significant patient population with diagnoses that complement the Medpace areas of specialization in cardiology, metabolism, and oncology. Enrollment tends to be 2 to 10 times that of Western countries. Strong patient / physician relationships result in high patient retention and protocol compliance. Select Eastern European countries have comparatively high numbers of either treatment-naïve or suboptimally treated patients who are highly motivated and in need of otherwise unavailable, free-of-charge drugs during clinical trials. These factors lead to Medpace reaching specific recruitment goals faster and with fewer sites.

Data

The high degree of accuracy in data obtained from clinical trials performed in CEE countries is attributed to large numbers of qualified medical specialists and staff, an educated and compliant patient population, clinical experience of the sites, and the ethical care and compliance with Good Clinical Practice (GCP) guidelines.

Regulatory

The implementation of the European Clinical Trial Directive (EU CTD) by EU member states benefited the clinical trial supply process by terminating custom barriers, reducing costs, and minimizing lead-in time. Medpace staff keep abreast of continuous changes in the regulatory environment, utilize their clinical trial submission expertise, and work to international standards.

Reaching a Global Population

Medpace Worldwide

Patient recruitment is the greatest obstacle in clinical trials today. Finding the right patient populations has fueled the rapid international growth of Medpace. With operations in nearly 40 countries, Medpace is well-positioned to meet changing client needs. Medpace offices are located in Africa, Asia/Pacific, Australia, China, Eastern Europe, India, Latin America, the Middle East, North America, and Western Europe.

Medpace is focused on making every global study cost-effective and well-organized. Start-up and efficiency metrics are maintained for each country where trials are conducted. Medpace assists sponsors in prioritizing international sites, not only by patient populations, but also by start-up speed and relative cost.

Clinical Research Associates (CRAs) are regionally-based and have in-depth knowledge of the local culture, language, and regulatory environment where they work. Medpace CRAs typically are assigned just two protocols each. They gain a thorough understanding of the therapeutic area and protocol, which allows them to communicate knowledgeably with investigators.

Therapeutic Areas of Expertise

Oncology

Oncology clinical trial development is longer and more intricate than trials in any other therapeutic area. The complexity of this development requires the right kind of research partner.

At Medpace, a unified team of oncology experts and highly knowledgeable clinical operations staff are prepared to quickly provide clients with the efficacy and safety data needed to support product approval worldwide.

Medpace has experience in classic multi-cytotoxic agent and targeted and/or biologic therapy trials and has conducted oncology trials throughout the world.

Cardiology and Metabolism

Medpace is home to renowned regulatory and therapeutic experts who are committed to the complex and intertwined therapeutic areas of cardiology and metabolism.

The medical team includes international therapeutic leaders who have helped pioneer many of the preventative cardiovascular and metabolic compounds introduced in the last 15 years.

Medpace regulatory experts are former government regulatory officials who have invaluable insight into the specific areas of cardiovascular and metabolic drug approval.

The Medpace Difference

The Advantage of Focus

Medpace is a global, research-based drug development company led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically-focused team to execute at all levels of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically-focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and executing to product approval.

With clinical trial experience in over 40 countries, Medpace has the global reach and capacity to conduct studies and navigate regulatory requirements worldwide. The Medpace approach creates therapeutically-focused project teams and increases the quality of every service offered.

Medpace group of companies

Medpace

Imagepace

Medpace Bioanalytical Laboratories

Medpace Clinical Pharmacology

Medpace Reference Laboratories